Previous month:
July 2012
Next month:
September 2012

Hair Loss from Scars or Injury? FREE Hair Repair is available!

FREE Hair Repair...  Have you or someone you know suffered scalp hair loss from scarring or surgery? Eyebrow loss or eyelash loss due to an accident, hair extensions, weaves, eyelash extensions or other injury?  We want to hear from you!  Nationally-recognized transplant surgeon, Dr. Alan J. Bauman, may perform your hair restoration treatments including hair transplant procedures FREE, including travel, at absolutely no cost to you through “Operation Restore” the ISHRS pro-bono hair restoration program. Do not delay, this is a limited program.

Email Dr. Alan J. Bauman, M.D. at or call 1-561-394-0024 before September 2nd, 2012.

L'Oreal introduces NeoGenic with Stemoxydine to target hypoxic scalp follicles

The following article is from

In September 2012, cosmetics company L’Oreal will introduce a new development in bio-technology that’s designed to not only stop hair loss, but also stimulate greater density and new growth. The product is called Neogenic, and the implications are very promising for the millions who suffer from hair loss and pattern baldness.

A step up from Aminexil

Previously in the battle for hair restoration, L’Oreal introduced a line of hair loss prevention products based on a synthetic molecule called Aminexil. The product improves the anchored strength of hair by acting on the collagen structure that surrounds the follicles—thereby keeping more of it on your head, and less on your comb or brush and down the drain.

However, the second-generation molecule created for Neogenic aims to actually produce thicker hair, and may even stimulate hair growth in areas where the follicles have shut down.

How Neogenic works

The latest development from L’Oreal is another synthetic molecule, with a stunning new approach. Called stemoxydine, this active ingredient works to counteract hypoxia—a condition that’s known to contribute to hair loss and balding. Hypoxia is a decrease or deprivation in oxygen supply. The condition can be serious, such as with generalized hypoxia, which limits oxygen intake throughout the body. But hair loss is a symptom of tissue hypoxia that affects the scalp—it’s been proven that hair follicles without growth are surrounded by oxygen-deficient microvasculature.

Stemoxydine targets this condition, attempting to increase oxygen levels in the tiny vascular structures of the scalp. The molecule acts upon hair-derived stem cells, improving their regenerative potential and maintaining function so new growth can occur.

Miracle or snake oil? Clinical trial results

Neogenic is the first hair growth product in quite some time to come with clinically proven effectiveness. The product has undergone patenting and testing through both in vitro models and live clinical studies, and results have been highly encouraging.

In a double-blind study of 100 men between the ages of 18 and 55, a once-a-day application of Neogenic was found to increase hair density by 4 percent. This may not sound like a lot, percentage-wise, but when you consider the actual numbers, 4 percent represents an average of 1700 new hairs.

Neogenic not only thickened hair, it also “woke up” follicles that had been dormant and stimulated new growth.

How to use it, and what it will cost

L’Oreal will debut the new product in September, at first available in France, where the company is headquartered. At its release, Neogenic will only be available in lotion form. The product should be rubbed into the scalp once a day, and results may be seen in as little as one month.

The debut price for a 24-pack supply, or one month of treatments, will be 90 euros—which equates to around US$110. Though the price tag is a bit steep, it’s likely to come down in time.

L’Oreal also plans to introduce other products featuring stemoxidyne as an active ingredient, including mousses and shampoos, in the near future.


Susan Thompson writes regularly on health topics for a variety of magazines and websites.


Unfortunately, L'Oreal's new product seems to be targeting a proposed mechanism for hair loss that to date, remains unproven. We know that the primary cause of hair loss in men and women is not poor blood flow or poor 'oxygenation' of the scalp. [Having performed 7,000+ hair transplants, I can tell you that even 100% bald scalp bleeds and heals well.]  In men, the primary trigger for hair loss is the detrimental effect of DHT (dihydrotestosterone) in the bloodstream.  Current research shows that DHT causes hair follicles to miniaturize according to a patient's genetic susceptibility. And, increases in 'density'--or the absolute numbers of hairs per area of scalp--once hair follcicles are dead and gone is not likely. However, if the product does in fact improve the length, caliber or pigmentation or another quality of thinning hair, this change should be able to be easily measured in 90 days with a HairCheck(TM) measurement. HairCheck is a scientific cross-sectional bundle measurement which can accurately track very small changes in hair caliber or density.  Time will tell whether the 'scientific-sounding' Neogenic with Stemoxydine will be a helpful addition to a hair loss treatment regimen which might include minoxidil (otc or prescription versions like Formula 82M), laser therapy, finasteride/propecia and hair transplantation. --Dr Alan Bauman, M.D.  Diplomate, American Board of Hair Restoration Surgery

LaserCap low level laser therapy for hair featured on ABC The View


 LaserCap™, The Portable Low-Level Laser Device for Thinning Hair, was featured on ABC's Emmy® Award winning talk show, The View
Renown LaserCap™ physician, Dr. Doris Day, was interviewed by Barbara Walters & Elisabeth Hasselbeck, during Hair Loss Awareness Month on ways women can fight hair loss.

MIAMI, Aug. 6, 2012 /PRNewswire/ -- On Friday, August 3rd,  LaserCap™ physician and New York-based dermatologist, Dr. Doris Day, appeared on ABC's Daytime Emmy® Award winning talk show, The View, presenting the LaserCap™ device to millions of television viewers across America. Barbara Walters and Elisabeth Hasselbeck interviewed Dr. Day.
In the segment, Dr. Day discusses the different types of hair loss in women and the ways that they can fight hair loss - from cortisone injections on the scalp to the LaserCap™ for home use.
Doris Day, MD, is a board certified dermatologist who specializes in laser, cosmetic, and surgical dermatology on the Upper East Side in New York City. Her private practice includes national and international celebrities.
Dr. Day speaks highly of LaserCap™: "What I love about this is that it treats the whole scalp at once in twenty minutes.*"
August is Hair Loss Awareness Month in the United States. Dr. Day reported that there are nearly 30 million women who suffer from hair loss.
The LaserCap™ ground-breaking device uses low level laser light to stimulate hair growth for hair loss at levels never before seen for at-home use. The device is hands-free, completely portable and easy to use, fits comfortably in almost any hat, is convenient and discreet, and can be used at home or on-the-go. The device is medically managed, and is only available through a licensed physician, but there are no weekly trips back to the doctor's office required (as in the case of the less powerful laser hood devices**).
*The recommended time for usage is 30-60 minutes every other day, but this may vary according to physician instructions.
LaserCap™ was created by Michael Rabin, MD, in collaboration with internationally recognized hair restoration surgeon, Robert Haber, MD, Harvard-based photomedicine expert, Michael Hamblin, PhD, and MIT-trained optical physicist David Smith, PhD. The LaserCap™ offers patients the low level laser power of an in-office clinical unit in the comfort of their home. It features 224 individual 650nm 5mW lasers in a flexible, hermetically-sealed dome-shaped membrane that fits comfortably in almost any hat, and is powered by a small belt-clip battery pack.
The LaserCap™ has not yet been cleared by the FDA as the FDA clearance process takes some time; however there are two laser devices that have received FDA clearance for hair re-growth, a hand-held comb-like device with 9 lasers for men and an in-office laser hood with 90 lasers for women. LaserCap™, with 224 lasers uses the same laser as both these devices.
LaserCap™ Founder and Co-Inventor, Dr. Michael Rabin: "We've been getting fantastic results. It slows the loss, stops it, reverses it in almost every patient."
Its ease of use leads to better efficacy and thus better results than other LLLT treatments because the treatment protocol is easy to follow.
"The LaserCap™ maximizes patient compliance since it is worn under any head cover (baseball cap, scarf, etc.) and is completely portable...higher dosimetry combined with consistent regular use (i.e., patient compliance) may be essential for effectiveness," said Robert Haber, MD, respected hair restoration surgeon and president of LaserCap Co.
Thinning hair is a condition that affects up to 50% of adult women and 80% of adult men. Thousands of LaserCap™ kits have been sold in countries across the world such as  USA, Australia, Brazil, Dubai, India, Italy, Kuwait, South Africa, Sweden, Venezuela, Dominican Republic.
**Leading In-Office Laser Hood Device has only 82 lasers, compared to LaserCap's 224. LaserCap's total laser output us 1120 mw compared to the leading In-Office Laser hood device which outputs 410 mw of laser.

Bauman Medical Group is proud to be amongst the first physicians worldwide to offer LaserCap low level laser therapy. Track your results from LaserCap using the patented, scientific measurement tool called HairCheck(TM).  HairCheck(TM) measurements are recommended before starting any hair regrowth treatment regimen. 

For more information on LaserCap, visit

or contact Dr. Alan J. Bauman at


Live Female Hair Transplant using NeoGraft FUE webcast on August 8th

image from
Bauman Medical Group to Feature First Female NeoGraft Hair Transplant Live Webcast on August 8th for National Hair Loss Awareness Month


Internationally renowned hair loss expert Dr. Alan J. Bauman will also discuss new diagnostic tools and treatments to prevent and fight female hair loss.


Boca Raton, FL – Hair loss is typically thought of as a “man’s disease,” but the truth is that women are almost just as at risk as men. In honor of August’s National Hair Loss Awareness Month campaign, internationally recognized hair transplant surgeon Alan J. Bauman, M.D. is performing the first-ever live webcasted female hair transplant using the minimally-invasive NeoGraft/FUE technique on Wednesday, August 8.


“Hair loss is a problem that affects more than 30 million American women,” Dr. Bauman said. “But, unlike male pattern hair loss which is more socially acceptable in our society, female hair loss is less understood and can lead to extreme emotional distress for those women who suffer from it. My goal with this live broadcast is to pierce the veil of secrecy surrounding women’s hair loss and show women that they’re not alone, and that effective treatment options are available to help. Not all women have to undergo transplants; in many cases early preventative treatments can be used - like Formula 82M Minoxidil, Propecia® (for post-menopausal women), Low Level Laser Therapy (LLLT) with LaserCap™ and even scalp treatments with Latisse.”


“The bottom line here, is that female pattern hair loss is treatable, and it’s also preventable – women just need to learn about their options,” Bauman said.


The live female hair transplant begins at 10amET/7amPT (14:00 GMT) when Dr. Bauman will discuss and demonstrate the NeoGraft FUE minimally invasive hair follicle harvesting method. Similar to his previous live surgery events, the webcast includes a live ‘call-in’ Q&A segment hosted by best-selling author and The Bald Truth radio talk show host, Spencer Kobren, and is to be syndicated on Andrew Zarian’s GFQ web radio network, which will take place at 12noonET/9amPT (16:00 GMT)


The hair transplant procedure will be live streaming to a global audience on Dr. Bauman’s Livestream channel: Viewers can ask live questions on Twitter @DrAlanBauman using the #hairtransplantnow hashtag.


The August 8th live female hair transplant event will show viewers a hairline lowering procedure to correct a receded hairline, enhance density at the hairline, temple areas and restore a widow’s peak. High hairlines can be a source of concern for women as they create a masculine look and often cause women to appear older than they are. It can also lead to problems and limitations with hair styling.  Bauman will perform the minimally-invasive surgery using NeoGraft FUE – a new minimally-invasive technique that makes it easier to extract hair follicles from the back of the head for transplantation in the front hairline and leaves no linear scar.


While the live event will focus on hair transplantation, Bauman will also be discussing and explaining the following hair loss treatments for women:


  • Non-Invasive Treatments for Women: In addition to hair transplants, there are an abundance of non-invasive treatments for female hair thinning, including prescription minoxidil “Formula 82M” as a stronger alternative to Rogaine for Women, the cordless and hands-free low level laser therapy device LaserCap™ and even Latisse™ (the popular celebrity eyelash drug). Bauman will also weigh in on the importance of nutrition for healthy hair and stimulating healthy hair growth with vitamin supplements like Viviscal and Biotin.
  • HairCheck: Simple, painless, non-invasive way to measure and track the amount of hair growing in a given area of scalp (called your Hair Mass Index or "HairNumber"). This information allows patients to follow and track their treatment to maximize effectiveness.
  • Genetic Hair Loss Testing: More than half of all women over 40 experience some degree of hair loss or thinning. But how do you know for sure if you’re at risk or if a particular treatment will work? New genetic tests can accurately determine a person’s risk for losing hair so they can begin preventative treatments early.
  • Cell Therapy: Helping the body heal itself through cell therapy is a hot trend today in medicine.  The use of autologous Autologel™ PRP (platelet rich plasma) for graft storage and wound healing with hair transplants and as a stand-alone treatment for enhancing hair growth is becoming more widespread as research continues. The application of PRP to the scalp requires short outpatient visits every eight to twelve weeks.
  • Eyebrow Transplants: Are your eyebrows sparse from years of over plucking? Despite increased consumer interest (from 2008 to 2010 eyelash/eyebrow transplants increased 14.2 percent), there is still a lack of information available on these cutting-edge procedures. Bauman will discuss the minimally-invasive, same-day procedure, where donor hair is extracted one follicle at a time and harvested and implanted into the eyebrow. 


For more information on the Bauman Medical Group, please visit or call 1-877-BAUMAN-9 or 561-394-0024.



Alan J. Bauman, M.D., founder of Bauman Medical Group in Boca Raton, Florida, is a full-time board-certified and internationally renowned hair transplant surgeon whose pioneering work has been featured extensively in the national and international print and television media, such as Newsweek, The New York Times, Cosmo, Vogue, Allure, Men's Health, Today Show, The Early Show, Good Morning America, Extra, Access Hollywood and Dateline NBC.


Dr. Bauman is recognized within the medical profession as top U.S. medical expert on the treatment of hair loss in men and women. A board-certified hair restoration surgeon, Dr. Bauman was the first to demonstrate ‘live’ the FUE method of hair transplantation at the 2003 International Society of Hair Restoration Surgery Orlando Live Surgery Workshop and the first to demonstrate the NeoGraft FUE device at the ISHRS Orlando Live Surgery Workshop in 2010. His practice is divided equally between male and female patients, and Dr. Bauman provides state-of-the-art diagnostic procedures and a multi-therapy approach to the medically treatable condition of hair loss. Dr. Bauman is a member and often a featured speaker at the American Academy of Anti-Aging Medicine and the International Society of Hair Restoration Surgery Annual Scientific Meetings. 


CNN reports Propecia Side Effect Study Author Received Compensation from Attorneys

Approximately two minutes into the CNN report below, it was revealed by investigative journalist Elizabeth Cohen that the author of the now infamous 'scientific study' of 50 men who reported persistent side-effects from the hair loss drug Propecia has received thousands of dollars in financial compensation from class action lawsuit attorneys.

Here is the transcript of the CNN report:July 13th, 2012 CNN

July 13th, 2012 CNN [**12:49:29 PM**] If you're sitting here with thinning hair thinking about popping a pill, a popular drug taken by millions of men to fight baldness could be causing major sexual side effects even after stopping taking the pill. Our senior medical correspondent, Elizabeth Cohen, there is a new study that is out now. What does this reveal? Let me step back and give some context to the new study. Years ago merck which makes the drug did a study. Years ago there was a study, where they took 900 men and put them on propecia and about 900 men and put them on placebo and they followed them to see if they had sexual side effects among other things. So here's what they found. So they found that the men taking Propecia 3.8% developed sexual problems like erectile dysfunction, and the men taking the placebo, only 2.1% developed sexual problems. We see both those numbers are tiny, but the difference between the two groups is statistically significant. Now we'll get to the current study. The current study looked at a 54 men on propecia who were having sexual problems. And most of them were on a website for men on propecia with sexual dysfunction. 54, very small number, and what the study found was that about 90% of them were having sexual problems even after they stopped taking the drug. So even after they discontinued, some of them apparently for years. So what does the drugmaker say about this study? The drugmakers say there's no proof that their drug is causing sexual problems that last even after men stopped taking the drug. Here's their statement. A causal relationship between the use of propecia and continued sexual dysfunction after the treatment has been discontinued has not been established. That the lack of cause and effect for sure has not been established. What about who's actually funding the study? Because you always want to get to the bottom of that, whether or not there's any kind of bias. Right, we always want to look at money. The big study, the merck study that showed that there was a low incidence of sexual problems that was funded by Merck. This study that looks at the men with sexual problems and showed that it lasted a long time the doctor who did that study has taken money from law firms that are suing merck because of sexual problems, so he has taken money from lawyers who are suing merck. He says he's taken less than ten thousand dollars. So bottom line should men be concern about this drug? Here's what the FDA has to say, the FDA is very clear. They say that men have reported certain sexual side effects that have lasted after they stopped taking the drug. Let's take a look at these, men have reported getting erectile dysfunction, libido changes, ejaculation disorders, orgasm disorders that lasted after stopped taking the drug. Might this drug give you sexual problems? Do you want to take that possible risk so that you can have more hair on your head? Maybe. Maybe not. We can't answer that question one hundred percent. That's basically the question that you have to ask yourself, you can go to your doctor and say is there another drug I can take? Is there something else I can do, otherwise just live with thinning hair that's another option.

Q: What is the incidence of sexual dysfunction in the General Population?
A: "Based on the few available community studies, it appears that sexual dysfunctions are highly prevalent in both sexes [in the general population], ranging from 10% to 52% of men and 25% to 63% of women. Data from the Massachusetts Male Aging Study (MMAS) showed that 34.8% of men aged 40 to 70 years had moderate to complete erectile dysfunction, which was strongly related to age, health status, and emotional function." --Edward O. Laumann, PhD. JAMA. 1999; 281(6):537-544

Treatment options for those with thinning hair or hair loss include topical medications (prescription 82M minoxidil or over-the-counter), low level laser therapy, nutritional supplementation and hair transplantation. Contact your American Board of Hair Restoration Surgery (ABHRS) certified Hair Restoration Physician to discuss your hair loss treatment options. Many thanks to Consumer Advocate, best-selling author, talk show host and American Hair Loss Association 501(c)3 founder, Spencer Kobren, for bringing this to the public's attention.  Sincerely, Dr. Alan Bauman